Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) reported positive results from midstage clinical trial of its chronic kidney disease treatment Zerenex. The stock price leaped $2.08 to close at $13.18.
Keryx Reports Positive Trial Results
November 05, 2013 at 11:03 AM EST
